Zomedica Q3 net loss narrows 48% to $3.2 million; Q3 revenue rises 22% to $9.9 million

Bitget2026/11/04 21:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zomedica’s third-quarter 2026 net loss narrowed 48% year over year to $3.2 million.
Revenue climbed 22% year over year to a third-quarter record of $9.9 million.
Diagnostic revenue more than doubled year over year to $1.6 million.
Operating expenses fell 21% year over year to $9.5 million; quarter-end cash, cash equivalents and available-for-sale securities totaled $40.9 million.
An agreement with Veterinary Study Groups created an opportunity to bring its products to more than 2,000 independent veterinary practices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zomedica Q3 net loss narrows 48% to $3.2 million; Q3 revenue rises 22% to $9.9 million

You may also like

Crypto prices